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Commentary
Hormesis can be broadly defined as a binary 
response phenomenon with low-dose stimula-
tion (or inhibition) of effects by substances 
producing opposite responses at a high dose. 
A more far-ranging definition from Calabrese 
and Baldwin (2002) states hormesis to be an 
adaptive response having similar biphasic dose–
response features as to amplitude and range, 
with the stimulatory response being either 
directly induced or compensatory following 
disturbance of homeostasis. This definition was 
expanded by Calabrese et al. (2007a), propos-
ing to stratify hormesis into three categories of 
hormetic expressions to better accommodate 
varying perceptions of the term.
Work by hormesis proponents over the last 
10–15 years has included developing a body of 
ad hoc scientific approaches specific to horme-
sis and mixing ad hoc science with relatively 
strong advocacy, using diverse mecha  nisms 
for hormesis development as a biologic topic 
in dose–response toxicology, human health 
risk assessment, and environmental regulatory 
policies.
The development and extensive employ-
ment of ad hoc methodologies for horme-
sis characterization and presenting that 
characterization within an idiosyncratic, tai-
lored vocabulary are discussed below. 
Most of the systematized scientific activ-
ity on hormesis, organized to rationalize and 
charac  terize the topic per se, has been done 
by the University of Massachusetts-Amherst 
(UMass-Amherst) hormesis program led by 
Edward J. Calabrese. The bulk of that activity 
addressed chemical hormesis, with radiation 
hormesis getting relatively less attention. 
Ad hoc Scientific Methodologies 
for Detecting and Characterizing 
Hormetic Phenomena 
Promoting hormesis as a subject for study and 
characterization has followed various rationales 
and methodologies and employed ad hoc path-
ways, that is, methods specific to the case of 
hormesis characterization. These largely orig-
inated with Calabrese and colleagues. These 
workers did not address the nature and scope of 
putative hormetic phenomena by doing de novo 
hypothesis testing using only validly designed 
and executed studies for hormesis character-
ization. They elected to establish a searching 
and screening methodology for hormesis com-
monality in the published literature using ad 
hoc identification and characteri  za  tion criteria. 
Calabrese (2001) rationalized this choice on the 
basis of the rela  tively high cost and difficulty of 
carrying out de novo experimental studies when 
meaningful outcomes were far from assured. 
This search-over-experiment strategy, how-
ever, requires fundamental assumptions about 
the required ad hoc battery of de novo search 
and assessment criteria, the relative complexity 
and validity of which determine the extent to 
which claims for hormesis should be judged 
by the scientific community. They include 
the following: a) quantitative characteristics 
of hormesis in selected journals approximate 
those in all publications or in nature; b) the 
statistical complexities and limitations under-
lying data searching for hormetic phenomena 
do not void the validity of the results; c) any 
ad hoc search criteria evolved for hormesis 
searches have been validated for reliability 
in terms of sensitivity and specificity; and 
d) search methodologies and their results are 
fully transparent to outside parties.
The UMass-Amherst–based articles, sum-
maries, and commentaries published mainly 
in the last 8–10 years deal with discrete but 
expanding blocks of data, some of which 
have been presented in the open literature in 
confusing and overlapping time frames (e.g., 
Calabrese 2008; Calabrese and Blain 2005). 
Two core claims over the past 8–10 years—
that hormesis is a common biological phenome-
non and that it is relatively more common in 
terms of dose–response models than threshold 
responses—are principally rooted in publica-
tions winnowed from a large data set of articles 
noted below. The first claim, of significant fre-
quency, was by Calabrese and Baldwin (2001). 
These authors claimed primacy of horme-
sis over threshold dose responses in 2003 
(Calabrese and Baldwin 2003b). Published 
materials by Calabrese and colleagues on either 
side of this time frame consist largely of papers 
leading up to this key pair of articles or are 
subsequent additions of papers from other 
databases, such as those data for substances 
examined within the National Toxicology 
Program (NTP) (Calabrese and Baldwin 
2003a) or by the National Cancer Institute 
(NCI) (Calabrese et al. 2006, 2007b, 2008; 
Crump 2007). 
None of the key databases evaluated by 
the UMass-Amherst hormesis group and 
noted here (Calabrese and Baldwin 2001, 
2003a, 2003b; Calabrese et al. 2006, 2008) 
were developed to demonstrate or characterize 
hormesis. Hormesis-like data were sought in 
databases created for other purposes but hav-
ing doses judged to be below a no observed 
adverse effect level (NOAEL). Screening for 
hormetic phenomena through retrospective 
and ad hoc quantification criteria in studies 
not designed to show hormetic phenomena 
creates various problems. These stratify into 
problems with initial selection of databases and 
problems internal to processing these databases 
in terms of methodologic limitations.
According to Calabrese and Baldwin 
(2001), the first database (20,285 articles 
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screened from three journals) was representa-
tive of general studies in experimental toxicol-
ogy and pharmacology and a valid statistical 
selection for hormesis screening. However, this 
claim is quite problematic, given the skewed 
distribution of dose–response relationships via 
entry criteria in their Table 2 (Calabrese and 
Baldwin 2001). The journal Environmental 
Pollution yielded 251 total dose–response 
relation  ships from 3,058 articles published 
over 29 years. More than half [141 (56%) of 
the total dose responses] appeared during only 
3 years (66 in 1987, 50 in 1985, 25 in 1990), 
with almost half [116 (46%)] appearing in 
just 2 years, 1985 and 1987. The 141 dose–
response relationships appeared in 9 articles, 
and the 116 in 5 articles.
The journal Bulletin of Environmental 
Contamination and Toxicology produced 
206 dose–response relationships from 7,404 
screened articles produced over 33 years. Of 
these, 98 (48%) appeared in just 5 years (17 in 
1990, 27 in 1992, 26 in 1995, and 14 in 
both 1996 and 1997). These are contained in 
22 articles. The journal Life Sciences yielded 
211 dose–response relationships from 9,823 
screened articles over 24 years of publication. 
Of these, 128 (61%) appeared in 44 articles 
over just 4 years (26 in 1978, 27 in 1985, 33 
in 1992, and 42 in 1998). 
This clustering of dose–response relation-
ships also appears to show close inter  year 
clustering. For example, the highest tallies for 
dose responses in Environmental Pollution, 
50 and 66, occurred 2 years apart, 1985 and 
1987, respectively. Markedly clustered dis-
tributions raise several questions, such as the 
presence of serial publications over a relatively 
short time by a few groups of investigators 
employing a few experimental protocols, 
rather than a broad and even distribution of 
experimentalists and experimental studies. 
It is not possible from available information 
published by Calabrese and Baldwin to deter-
mine a basis for clustering.
Problems internal to the ad hoc identifica-
tion and characterization criteria evolved by 
these researchers affect both the number of 
articles that meet entry criteria and subsequent 
evaluation of those articles to confirm hor-
metic responses. These problems are methodo-
logic and statistical. The criteria have not been 
independently validated as to reliability, sen-
sitivity, and specificity (Kitchin and Drane 
2005; Mushak 2007), thereby weakening the 
assumption of validated ad hoc search criteria 
presented earlier.
The large BELLE (Biological Effects of 
Low Level Exposures) database described by 
Calabrese and Baldwin (2001, 2003b), among 
other things, was assembled at the outset to 
search for and identify the presence of hormetic 
data. Crump (2001) highlighted some of the 
special statistical problems associated with data 
searches and methodologies using criteria estab-
lished a priori. For example, one must correctly 
control for the false-positive rate in searching 
databases for a specific form of a phenome-
non, for example, hormesis-like data. Crump 
noted that if one is looking for hormesis-like 
examples within 100 published dose–response 
relationships in articles being searched, then 
the appropriate condition for statistical signifi-
cance to control for false positives requires that, 
for the standard level of 0.05, the more strin-
gent p-value estimated from the relationship 
1 – (1 – p)100 = 0.05, or p = 0.0005, is required. 
Calabrese and colleagues have taken general 
note of Crump’s statistical criticisms, such as 
replacement of scoring schemes with screening 
criteria. It is not evident, however, that they 
have implemented, rationalized, or appropri-
ately validated tests to apply statistical rigidity 
within screening criteria to minimize type 1 
errors through uniform use of more severe 
statistical tests, as noted by Crump (2001). 
For example, only one of the multiple tests 
within the evaluation criteria for ruling in hor-
metic response and ruling out false-positive 
frequencies in Tables 4 and 5 and Figure 2 of 
Calabrese and Baldwin (2001) is the statis-
tically accepted one of statistical significance 
(p ≤ 0.05). The assumption is that other tests 
show, for example, potential equivalence to 
statistical significance. 
Two components in determining frequency 
of hormetic responses in the large literature 
data set of Calabrese and Baldwin (2001) are 
the hormetic frequency determinations them-
selves and determinations of the numbers of 
false positives to permit adjustments to the 
claimed actual hormetic response rates. The 
two methodologies link closely conceptually 
and mathematically, as one cannot determine 
one without knowing the other. In addition, 
the determination of frequencies of hormetic 
effects and frequencies of false positives are 
both done within the same conceptual and 
methodologic framework, that is, approaches 
largely governed by arbitrary and unvalidated 
entry and evaluation criteria. Consequently, 
problems with either of these elements for the 
gross and adjusted frequency assessments attach 
to the other as well. 
The various and largely unvalidated 
cate  gories of total and hormetic-effect 
dose responses are set forth in Table 1 and 
Figures 1 and 2 of Calabrese and Baldwin 
(2001), and the false-positive estimating types 
of methodologies are shown in Tables 4  –6 
of the same paper. They used three types of 
entry and evaluation methods for estimat-
ing the total hormetic frequencies to include 
for inverse U-shaped hormetic effect curves: 
statistical significance, data distribution, and 
alternative quantitative methods, as defined 
by the authors. The data distribution method, 
involving absence of overlap in measures of 
variability, is held to be potentially statisti-
cally significant. The alternative quantitative 
method employed at least three data points 
where positive deflection from control (a hor-
metic response in cases of inverted U-shaped 
curves) was ≥ 110% of control, but it had no 
statistical basis for validity. Why use only the 
modest deflection value of 10% over controls? 
Lastly, the authors presented these methods 
with such low transparency that the reader 
must pay particularly close attention in track-
ing data generation and presentation.
One calculates the unadjusted and 
adjusted frequencies for the most reliable 
screening criterion, statistical significance—
using Figure 2 and Table 6 of Calabrese and 
Baldwin (2001)—to be 11% in both cases. By 
contrast, using the two more arbitrary meth-
ods plus that of statistical significance more 
than triples the figure, to 37% and 35%, 
respectively (Table 6). 
Calabrese and Baldwin (2001) estimated 
false-positive rates and nonrandomness for 
hormesis in the data set, that is, employed 
ratios of the percentage of stimulatory hor-
metic responses to the percentage inhibitory 
deflections from controls (false positives). For 
the case of inverted U-shaped hormetic curves 
[Figure 1 of Calabrese and Baldwin (2001)], 
stimulation or positive deflections versus con-
trols below the NOAEL is the numerator and 
inhibition below the NOAEL similarly applies 
for the denominator. Calabrese and Baldwin 
(2001) reported in their abstract that the false-
positive rate using their approach is 0.6%, 
derived from having seven false-positive doses 
and 1,089 total doses in the portion of the 
data set with two or more dosing points below 
the NOAEL.
The above picture becomes much less 
clear-cut when examining Tables 4 and 5 of 
Calabrese and Baldwin (2001). Table 4 is 
the basis for the authors noting the quite low 
false-positive rate of 0.6% and the associated, 
relatively robust ratio for hormetic over false-
positive effects of 32.5. Table 5, depicting 
the cases in the overall data set with three or 
more dosing points ≥ 110% of controls for 
the evalua  tion but using hypothesis testing, 
data distribution, and alternative quantitative 
methods for the entry criteria, shows a much 
higher false-positive rate of 22% for the least 
arbitrary entry criterion of hypothe  sis testing. 
The intermediate methodologic approach as 
to reliability—data distribution—shows a 9% 
false-positive rate. By contrast, the most arbi-
trary approach—alternative quantitative—
shows a 0% false-positive rate. That is, the 
least problematic and the most problematic 
approaches show the highest and lowest false-
positive rates, respectively. Last, a mathemati-
cal error in Table 5 erroneously presents the 
sum of positive instances of hormesis as 75 
instead of 57.Appraising hormesis methodology
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A critical determinant in how one interprets 
data of the type described by Calabrese and 
Baldwin (2001) is the nature of the experimen-
tal control populations. Responses in controls 
are the metrics against which the stimulatory 
and inhibitory frequencies are compared and 
determined. This is the case with all three cate-
gories of evalua  tion criteria they described in 
their article. Furthermore, control responses 
figure in estimating the relative primacy of hor-
metic over threshold dose responses as claimed 
by Calabrese and Baldwin (2003b). 
A particular issue with the statistical nature 
of experimental control populations is that the 
relative excursions of hormetic responses versus 
controls are quite modest, and therefore such 
responses may lie within the collective experi-
mental control population variability when 
hundreds of different hormetic effects are win-
nowed from thousands of publications. This is 
in contrast to the relatively wide differences in 
occurrence of adverse effects versus controls on 
dose–response curves above NOAEL values.
Questions arise with respect to this critical 
role of experimental controls. The level of vari-
ability in responses in control groups within 
very large data sets would be expected to affect 
the relative reliability of identifying hormetic 
effects when controls are in the testing proto-
cols within the large screening data sets and 
affect the frequency of hormetic effects. It 
is not clear from the available evidence that 
control group variability can be readily iden-
tified and quantified in hormetic characteriza-
tions, nor is it clear that hormetic responses 
are quantitatively in excess of the extent of 
variability. The analyses of Mayo and Spanos 
(2008) and Zapponi and Marcello (2006) 
address the nature of control group responses 
and their role in hormesis characterization.
Mayo and Spanos (2008) cautioned 
that adequate attention to deficits in various 
articles by Calabrese and colleagues, such as 
absence of statistical significance tests for hor-
metic responses, described in the critical com-
ments of others, is lacking. They pointed out 
that hormetic effects are claimed via rela  tively 
unsevere tests. They also noted the Calabrese 
et al. approach, using entry criteria, gives 
closer scrutiny to cases where such effects 
occur with a high incidence among controls. 
Zapponi and Marcello (2006) also addressed 
idio  syncratic control responses and pointed 
out a number of situations where claimed 
hormesis is driven by high-effect incidence in 
controls and is rarely statistically significant.
Calabrese and Baldwin (2001) claimed 
that the 20,285-article database revealed 
245 hormetic-type responses in 86 articles, 
0.42% of the original tally. The total count 
of 668 dose responses was contained in 195 
articles (~ 1%) (Calabrese and Baldwin 2001). 
The 245 (37%) hormetic responses, however, 
are derived from a variety of data evaluations, 
only 74 of which met the minimal accepted 
scientific criterion of statistical significance 
(p ≤ 0.05) [Figure 2 of Calabrese and Baldwin 
(2001)]. This statistically significant hormetic 
dose–response percentage is 11% (74/668) 
of all dose responses and approximates that 
found in a study by Davis and Svendsgaard 
(1994) using data from a broader range of 
journals, 12–24%.
The second core claim, that hormesis is 
more common than threshold responses, is 
rooted in three reports. The first relies on a 
problematic statistical premise described by 
Calabrese and Baldwin (2003b). They cal-
culated the ratio of the numbers of dosing 
points below the NOAEL but above control 
responses (A) to the dosing numbers below 
the NOAEL and below control response (B) 
for almost 1,800 dosing points contained 
within 664 dose–response relationships to be 
2.5:1, favoring points above control responses 
(i.e., stimulation). They found this ratio to be 
significantly different statistically from 1.0. 
This was taken as evidence of hormesis pri-
macy over threshold responses, as the reverse 
outcome requires the A/B ratio be about 1, 
from a random distribution of dosing points 
above and below control responses.
However, the data points were not gath-
ered from a purely random sampling within 
the main database for use in the A/B ratio 
test, but from dose–response relationships 
meeting the unvalidated, ad hoc entry criteria 
for data having potential hormetic charac  ter 
and meriting further assessment. The ratio test 
employed by Calabrese and Baldwin (2003b) 
considers only deflections above and below 
controls for isolated dosing points stripped 
from entry dose responses contained within 
preselected articles. 
A truly random data set for purposes of 
this particular ratio test should include the 
additional dose responses with only single sub-
NOAEL dosing points in terms of deflections 
in either direction. These dose responses and 
publications with them are not statistically 
confined to the population of dose responses 
meeting the entry criteria for hormesis screen-
ing of two or more individual points below 
the NOAEL. Randomness in this expected-
to-be larger count of individual dosing points 
(vs. the 1,791 dosing points) combined with 
the 1,791 dosing points actually employed 
would reduce the value of any resulting ratio 
to < 2.5 and potentially to a value not signifi-
cantly different statistically from 1.0.
A further difficulty, made worse by lim-
ited transparency for changes in analysis of 
data sets over the course of the articles, is that 
the complementary analysis data reported by 
Calabrese and Baldwin (2001) showed that 
80% of the 1,089 data points below the 
NOAELs were not different from controls (vs. 
only about 20% with hormetic character) and 
therefore consistent with a threshold response 
model. How the 1,089 dosing points reported 
by Calabrese and Baldwin (2001) relate 2 years 
later to the 1,791 data points claimed to clearly 
show the presence of hormetic over threshold 
responses (Calabrese and Baldwin 2003b) still 
awaits explanation.
Last, what is the conceptual and statistical 
validity of stripping hundreds of individual 
dosing points from lower numbers of intact 
dose–response curves representing various 
substances, numbers of points, end points, 
experimental and biological systems, etc.? For 
example, a dose–response curve for substance 
X with four or five sub-NOAEL dosing points 
and concurrent controls with a high response 
rate for the specific end point gives dosing 
points that would be added to two sub-NO-
AEL points on a dose–response curve for sub-
stance Y, from a study using controls with a 
low response rate for that specific end point. 
On its face, the practice appears to inform the 
issue of (non)randomness, but the (non)ran-
domness of what exactly? Allied to this, why 
are such analyses not confined to the intact 
dose–response curve as the statistical unit for 
testing?
Elliott (2008a) drew attention to some 
difficulties of ignoring distinctions between 
isolated dosing points and intact dose–re-
sponse relationships. One mathematical con-
sequence of the distinction is that if there is 
a random (i.e., 1:1) distribution of hormetic 
to threshold responses, the ratio of the corre-
sponding isolated dosing points under certain 
assumptions would approach 3:1. This ratio 
can be compared with the ratio estimated by 
Calabrese and Baldwin (2003b).
Any claim that hormesis is the most com-
mon dose–response model requires that it be 
the major model mathematically and be shown 
to be so using dose–response data analysis for 
other candidate dose–response models. One 
cannot make quantitative (percentage) esti-
mates of hormesis occurrence simply by leav-
ing uncharacterized the residual information 
remaining after winnowing the hormetic dose 
responses meeting a priori criteria. Second, 
stating a percentage frequency of one of several 
options for some quantitative metric (dose–
response relationships) assumes one knows 
the nature of the other dose–response mod-
els and their frequencies. Hormesis is clearly 
not the principal dose–response model in the 
Calabrese and Baldwin (2001) report, being 
only 11% (74/668) using the established stan-
dard of statistical significance (p ≤ 0.05) for the 
best evidence, or 37% (245/668) of all entry 
dose–response relationships when using statis-
tical significance plus the various Calabrese and 
Baldwin (2001) unvalidated evaluation criteria.
What, then, are the dose–response models 
comprising the balance of the percentages in, 
first, the Davis and Svendsgaard (1994) data, Mushak
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given that hormesis was sought in all the data 
sets using several ad hoc criteria but found in 
only 12–24% of tested cases? The Davis and 
Svendsgaard database consists of results for 
noncarcinogens, and the remaining 76–88% of 
dose responses would be threshold responses. 
In Calabrese and Baldwin (2001), the 11% 
value using the statistical significance criterion 
or their more arbitrary 37% figure suggests 
that nonhormetic dose–response relationships 
exist in the majority of cases. 
The articles by Calabrese and colleagues 
describing assessments of hormetic phenom-
ena embedded in data from other journals 
principally probed the scope of hormesis-like 
phenomena devoid of frequency estimates. A 
number of these are noted in Mushak (2007).
These later articles presented individual cases 
of hormetic phenomena, cases not charac-
terized as to their frequency. All one knows is 
that in the specific cases identified, a hormetic 
response was claimed.
An important question concerns the scope 
of the Calabrese and Baldwin frequency figure 
of 37%, or 11% using the less arbitrary statis-
tical significance test. If the remaining 99.6% 
of the 20,285 screened articles had contained 
sufficient dose ranging and met other ad hoc 
entry and evaluat  ion criteria, what is the likeli-
hood that 37% (or 11%) rather than 0.4% 
of the 20,285 raw article base would have 
contained hormesis-revealing dose–response 
relationships? That is unknown, but Calabrese 
and Baldwin (2001) leave one to infer 37%.
Calabrese and Baldwin (2003a) also evalu-
ated data from NTP dose-ranging studies and 
noted these have the advantage, among other 
things, of using five dosing points per testing. 
Calabrese and Baldwin (2003a) actually illus-
trated the high potential for misstatements and 
contradictions in interpretations and conclusions 
when using problematic ad hoc methodologies.
Calabrese and Baldwin (2003a) claimed a 
significant frequency of hormesis across test-
ings for 58 substances examined by the NTP 
program: 51 substances were said to show 
hormetic effects, 48% of bioassays involving 
mice and 14% of bioassays involving rats were 
said to show hormesis, and hormetic effects 
were said to be present in 128 of 409 (31%) 
dose–response relationships. A different pic-
ture emerges when looking at the strength 
of the actual evidence for the 128 hormetic 
responses. Calabrese and Baldwin (2003a), 
using a ranking scheme developed earlier, 
noted that 76% (98/128) of the 128 relation-
ships yielded low evidence of hormesis, 16% 
(21/128) showed low-to-moderate evidence, 
5% (6/128) showed moderate evidence, 1.5% 
(2/128) showed moderate-to-high evidence, 
and 0.8% (1/128) showed high evidence.
Of 409 total dose–response relationships, 
only 0.73% (3/409) showed moderate-to-
high or high evidence for hormesis, and only 
0.24% (1/409) presented with the most reli-
able (high) evidence. These frequencies do not 
provide strong support for the 31% frequency 
stated elsewhere in the same article or the 
37% (245/668) showing the best evidence of 
hormesis in Calabrese and Baldwin (2001). 
The second and third reports asserting the 
primacy of hormetic over threshold responses 
are those of Calabrese et al. (2006, 2008). 
They first reported that their examination 
of the large NCI yeast response screening 
database for anti  tumor drugs demon  strated, 
when 2,189 anti  tumor drugs were evaluated 
via 56,914 dose–response studies (five dos-
ings, 13 yeast strains, replication), that hor-
metic response patterns were observed about 
four times more frequently than would be 
predicted from statistical chance alone. They 
asserted that their findings call for rejection of 
the threshold dose–response model in favor of 
the hormetic one.
It is not known what claimed hormetic 
responses in yeast systems responding to anti-
tumor agents say about hormetic responses in 
biological systems at large, in human popula-
tions, or about the need to substitute hormesis 
for any other risk assessment dose–response 
paradigm in public health and regulatory 
policies. Secondly, use of this database by 
Calabrese et al. is complicated by the fact that 
only data summaries, not original data, were 
preserved by the NCI investigators. 
Crump (2007) took note of this gap in 
original data-handling details in criticizing the 
Calabrese et al. (2006) results, reporting that 
at least one of two plausible ways the origi-
nal NCI investigators could have statistically 
handled the control well data would eventually 
yield findings of hormesis-like responses—as 
a methodologic artifact—without hormesis 
being present. Calabrese et al. (2007b) rebut-
ted Crump’s claims, insisting that the original 
testing procedures at statistical issue in the NCI 
effort were correctly identified on the basis of 
information from the original investigators 
and a poll among outside investigators doing 
this type of research. Calabrese et al. (2007b) 
further asserted that Crump’s alternative data 
handling lacked credibility, as it was unlikely 
that his approach to data handling was used in 
the NCI studies. 
The critical question is which of these two 
equally plausible approaches for data handling 
of controls is correct for revealing the truth 
about whether actual hormetic phenomena 
are present in data sets generated in these NCI 
screening protocols, protocols not developed 
to elucidate hormesis per se. The counter-
claim that Crump’s approach for control 
data handling would probably not have been 
NCI’s does not appear relevant to this or a 
second critical question: Why is identifica-
tion of allegedly robust hormetic responses 
methodologically unstable in the first place? 
Identifying robust and stable hormetic effects 
should be independent of subtle nuances and 
details such as control data statistical handling. 
Because two equally plausible alternatives for 
control well data handling (regardless of what 
NCI investigators did) reveal two different 
outcomes regarding hormesis, the question 
about the validity of using the NCI data to 
prove robust hormesis commonality remains 
unresolved. 
Calabrese et al. (2008) offered two added 
claims in further analyses of the NCI data set. 
First, the percentage differences from con-
trols in overall responses are governed by an 
overall upshift in observed means versus pre-
dicted threshold dose–response means, mean-
ing overall hormetic expressions exist. Second, 
there are within the suite of tested chemicals 
a significant number that show strong effects. 
This study, like some of its predecessors, still 
raises concerns. First, there is the use of screen-
ing entry and other assessment criteria that 
remain to be validated as to sensitivity and 
specificity. Low transparency to the methods 
makes it difficult to judge some of the claims 
as to consistency with their other work and the 
objective basis for labeling responses as strong. 
Furthermore, the matter carried over from the 
Crump (2007) critique remains unresolved. 
It is not clear the extent to which the chosen 
method for dealing with control well responses 
affects results here versus the Calabrese et al. 
(2006) analyses. Calabrese et al. (2008) noted 
design and methodologic differences with 
Calabrese et al. (2006), but the earlier matter 
remains unresolved.
An example of ambiguity and inconsis-
tency is the conclusion of Calabrese et al. 
(2008) that, although certain treatments pro-
duced responses < 10% over controls and even 
responses below controls, these are still hor-
metic in character. However, the authors did 
not make clear why such subcontrol (< 100%) 
responses are not actually an expression of 
false-positive occurrences, as seen in Calabrese 
and Baldwin (2001). Furthermore, they held 
that responses ≤ 80% are inhibitory, further 
leaving the treatments within the remaining 
20% interval from controls uncharacterized. 
A second area of ambiguity and low 
transparency is exactly how the troublesome 
influence of control variability is sufficiently 
attenuated in their methodology. See the dis-
cussion above and those of Mayo and Spanos 
(2008) and Zapponi and Marcello (2006) 
about the critical role of high control group 
response rates vis-à-vis hormetic frequencies. 
There are no reliable bounding criteria for 
objectively categorizing strengths of chemical-
specific hormetic responses in Calabrese et al. 
(2008). In semantic terms, we have chemicals 
that produce differences in the end points 
claimed for hormesis but that may not trans-
late to variable strength in hormetic responses.Appraising hormesis methodology
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Finally, this second effort leaves intact the 
major concern about relevance of yeast strain 
results in Calabrese et al. (2006) to potential 
hormetic effects in humans and other higher 
biological systems. At the end of the second 
analytical and interpretive day, we are still 
limited to yeast systems.
The Language of Hormesis 
Characterization
The most recent incarnation of hormesis has 
been accompanied by a tailored vocabulary for 
the topic coupled with problems in language 
precision, yielding ambiguous and potentially 
misleading terminology. Language matters. 
Language especially matters with evolving 
and/or controversial scientific topics where 
communicating and interpreting new find-
ings must be done free of ambiguity. Parts of 
this customized vocabulary are not only ques-
tionable uses of settled meanings within the 
broader language but also serve to inflate such 
characteristics as the claimed scope and fre-
quency of hormetic phenomena in nature or 
published literature, and conflate hormesis in 
importance with existing pillars of risk assess-
ment and toxicology and with the universality 
of other biological phenomena.
The first language challenge is defini-
tion. Repeated redefinitions of hormesis have 
had mixed effect in systematically and con-
vincingly answering what hormesis is, why 
it exists, and why it is important. It is not 
clear that any final and clear definition exists 
for hormesis. Calabrese and Baldwin (2002) 
attempted a fairly comprehensive definition of 
the nature and under  lying biological purpose 
of hormesis in nature, settling on hormesis as 
an adaptive response.
More recently, Calabrese and a large 
number of coauthors attempted to present 
the rationales for an even more extensive 
definition (Calabrese et al. 2007a). Three 
expressions of the term were proffered, two 
centering on adaptive or conditioning phe-
nomena in response to biological stress, and 
the third encapsulating the conventionally 
understood form of hormesis. In this scheme, 
conditioning/adapting stresses and post-
exposure conditioning responses are allied 
with the conventional phenomenon of horme-
sis, with the latter not evincing conditioning or 
adapting dose responses. Where there was an 
interim notion, for example, of just “chemi  cal 
hormesis,” there are now two additional terms 
for responses to chemicals: “chemical condi-
tioning hormesis” and “chemi  cal post  exposure 
conditioning hormesis.”
The epistemologic difficulty with this 
attempted broader taxonomy by Calabrese 
et al. (2007a) is that it uproots the assump-
tion that chemical hormesis is a discrete 
phenomenon having a defensible definition 
that is amenable to a discrete quantitative 
characterization within reliable criteria while 
governed by a discrete overarching mechanism 
or mechanisms, and has a discrete function in 
nature that would better abet acceptance of a 
role in health and regulatory policy.
Hormesis as a specific term and concept, 
in terms of biological functions and mecha-
nistic under  pinnings, cannot be three different 
biological phenomena simultaneously. These 
floating expressions need to give way to dis-
crete, differentiating labels and a reassembling 
of current evaluatory approaches and databases 
to adequately validate each separately. 
The use of various terms for generaliz-
ability by hormesis advocates differs markedly 
from the broader definitions and uses of these 
terms (Mushak 2007). Cook and Calabrese 
(2006) referred to hormetic responses being 
“ubiquitous” in nature, but that definition 
(Merriam-Webster 2002) requires hormesis 
to be everywhere at all times (i.e., with 100% 
frequency of occurrence and with 100% fre-
quency at any and all times within a given 
testing or testing series). 
Calabrese et al. (1999) held hormesis to 
be a “highly generalizable and reproducible” 
phenomenon. “Generalizability,” although less 
semantically stringent than “ubiquity,” presup-
poses that hormesis, being highly generalizable, 
occurs in nature or in the literature with at least 
a more-likely-than-not occurrence (i.e., > 50%) 
in screened and evaluated literature. The evi-
dence does not support this. Data from two 
sets of investigators indicate absence of a 100% 
or even > 50% frequency of occurrence in pub-
lished literature (Calabrese and Baldwin 2001; 
Davis and Svendsgaard 1994). Nonetheless, 
the term is intractably ambiguous. Use of the 
term “reproducible” (Calabrese et al. 1999) as a 
characteristic of hormesis is equally ambiguous; 
these authors took the term to mean examples 
of hormetic responses for similar substances or 
classes across studies, whatever the frequency. 
Conventional use of the term is that differ-
ent investigators get basically the same results 
under the same set of experimental conditions. 
One troubling element of this customized 
vocabulary is the uncoupling or muddling of 
the link between frequency of occurrence and 
frequency as a critical determinant of gener-
alizability. Frequency of hormetic examples 
is treated separately by the UMass-Amherst 
group (Calabrese and Baldwin 2001) and is 
confined to analysis of a discrete database by 
Calabrese and colleagues. Frequency estima-
tions for hormesis do not appear as a core 
component of analysis of all the databases 
examined by Calabrese and colleagues. 
Generalizability for hormesis is apparently 
established here if one sees hormetic examples, 
regardless of overall frequency. This applies to 
the numerous examples summarized in the 
special issues of Critical Reviews in Toxicology 
as cited by Mushak (2007).
Finally, proponents appear to be incon-
sistent in applying the language for horme-
sis. Calabrese and Baldwin (2002) noted that 
hormesis defined as “direct stimulation” is 
modest stimulation, with too much stimula-
tion depicting some other phenome  non. This 
stance contradicts the basic definition of hor-
metic behavior, that is, the phenomenon is 
biphasic. The more stimulatory its expression, 
the more apparent the presence of hormesis. 
Their stance, furthermore, does not void the 
alternative possibility that modest deflections 
from controls are statistical artifacts and that 
strong stimulation is actually hormesis. 
Conclusions
What has been accomplished with hormesis 
over the last 10–15 years? Hormesis as term 
and concept is now less obscure and neglected 
than in past decades. A significant volume 
of information has appeared, much from the 
hormesis group at UMass-Amherst (Calabrese 
and colleagues). Although both chemical and 
radiation hormesis have been of interest to 
proponents, the former has been most heavily 
evaluated. Collateral awareness has been raised 
in various scientific and health policy quarters 
about the central role of quantitative toxi-
cology in the toxicologic and related health 
sciences via the dose–response relationship. 
Recent advocacy efforts by hormesis propo-
nents also illustrate that in any advocacy there 
is some measure of devil’s advocacy. That is, 
evaluation of hormetic response models forces 
equal scrutiny of other dose–response models, 
whatever the technical merits, limitations, or 
plausibility of hormesis. 
What has not been accomplished with 
hormesis in the last 10–15 years? Hormesis as 
a term and concept remains riddled with gaps, 
serious and valid questions about the science, 
and skepticism in scientific quarters over the 
relevance of hormetic phenomena to human 
health risk assessment and various regulatory 
policies. To date, hormesis has not been sub-
jected to systematic and arms-length collec-
tive scrutiny by scientific organizations such 
as the National Academy of Sciences/National 
Research Council or other recognized entities.
Furthermore, no public agency has adopted 
hormesis as part of risk assessment or regulatory 
policy or expressed any inclination to do so. 
Reasons for this inaction likely include linger-
ing skepticism, the topic’s relative immaturity, 
the nature of how activity on the topic over the 
last 10–15 years has been pursued, and even 
how one would do a hormetic risk assessment. 
The type and number of efforts by such 
proponents as the UMass-Amherst horme-
sis group have significantly formed and 
advanced the current status of hormesis, and 
it is unlikely that hormesis would be at its 
present stage without that involvement. Still 
open is the question of whether the efforts of Mushak
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the proponents simply accelerated and forced 
streamlining of the scientific gatekeeping 
process for hormesis and any potential roles 
in health, regulation, or other sectors versus 
taking the field in specific directions.
The specific methodologies and strategies 
employed by these workers in accelerating the 
study and promotion of hormesis have taken 
development of the topic in specific develop-
mental directions. The issue of the extent to 
which such progress has engendered any ethical 
dimensions has been addressed. Elliott (2008b) 
provided a broad analysis of ethical matters in 
summarizing a group of articles on the topic 
included in the August 2008 issue of Human 
and Experimental Toxicology.
Broad scientific acceptance of new or con-
troversial biological phenomena seems a plod-
ding and multidirectional process, and one 
that might well invite impatience. This impa-
tience would be amplified in those who accept 
that hormesis is basic biology and toxicology 
and also has something important to say about 
biological phenomena in general and dose–
response toxicology and pharmacology in par-
ticular. Calabrese (2002) stated that previous 
incarnations of hormesis failed to be accepted 
because of “a complete lack of strong leadership 
to advocate its acceptance in the right circles.” 
Rooted in any seemingly plodding pace 
of scientific oversight, however, are many 
mecha  nisms for auditing the potential survival 
of junk science, providing objective expert 
consensus through arms-length means, and 
providing wide scientific acceptance because 
of the efforts of many, not one or a very few. 
Where to for hormesis? Major advances 
in chemical hormesis beyond empirical curi-
osity will require convincing evidence that 
the phenomenon is relevant to higher orders 
of biological complexity, especially for dose–
response relationships in human popula-
tions. Such advances would have to precede 
considering chemical hormetic phenomena 
in human risk assessment and regulatory 
options. Biological relevance of chemical 
hormesis to human populations is hobbled 
by the same comparative empirical conun-
drum affecting other areas of biology and toxi-
cology, especially given its provisional status. 
The simpler the study system, the more easily 
charac  terizable, but the less its relevance to 
humans; the more biologically complex and 
closer the study system as a human response 
surrogate, the less easy the characterization, 
but the more confidence about relevance to 
humans. From the UMass-Amherst efforts, 
we have a good number of articles on rela-
tively simple biological systems but little hard 
biological evidence of the nature and extent 
to which hormesis operates in humans and 
human populatons.
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